规格 | 价格 | 库存 | 数量 |
---|---|---|---|
1mg |
|
||
5mg |
|
||
Other Sizes |
|
靶点 |
IC50: 14 nM (PTEN)[1]
|
---|---|
体外研究 (In Vitro) |
BpV(HOpic) (1 μM) 疗法可促进顺铂处理的 MG63 细胞的细胞分裂并降低细胞凋亡率 [3]。 Bpv(HOpic) (1 μM) 刺激 C2C12 成肌细胞迁移,与 PI3K/AKT 相互作用,并与 MAPK/ERK 信号通路激活相关 [4]。与人类和啮齿动物一样,BpV(HOpic(1 μM;48 小时)可刺激猪毛囊生长和发育的开始 [5]。纳米载体-BpV(HOpic) 可增强神经轴突发育 [2]。
|
体内研究 (In Vivo) |
再灌注后,BpV(HOpic (0.05 mg/kg; ip) 可改善体内肝脏缺血/再灌注 (I/R) 损伤[6]。暴露于 BpV (HOpic (200 μg/kg; ip) 损伤 (IRI) 的小鼠经历肾功能障碍恶化和肾小管损伤增加[7]。
|
动物实验 |
Animal/Disease Models: Male Wistar rats are subjected to partial hepatic ischemia[6]
Doses: 0.05 mg/kg Route of Administration: Ip injections at the start of reperfusion Experimental Results: Ameliorated reoxygenation injury and reproduced the hepatoprotective effects obtained by adenosine A2A receptor stimulation. Animal/Disease Models: Male C57BL/6 mice (8-12 weeks old; 20-30 g ) are subjected to renal ischemia[7] Doses: 200 μg/ kg Route of Administration: Ip injections 1 h before ischemia and then administers every 6 h after ischemia for 24 hr Experimental Results: Raised the level of serum creatinine and blood serum urea nitrogen. |
参考文献 |
[1]. Schmid AC, et, al. Bisperoxovanadium compounds are potent PTEN inhibitors. FEBS Lett. 2004 May 21; 566(1-3): 35-8.
[2]. Kim MS, et, al. Nanotherapeutics of PTEN Inhibitor with Mesoporous Silica Nanocarrier Effective for Axonal Outgrowth of Adult Neurons. ACS Appl Mater Interfaces. 2016 Jul 27; 8(29): 18741-53. [3]. Zhang B, et, al. Silencing of miR-19a-3p enhances osteosarcoma cells chemosensitivity by elevating the expression of tumor suppressor PTEN. Oncol Lett. 2019 Jan; 17(1): 414-421. [4]. Dimchev GA, et, al. Phospho-tyrosine phosphatase inhibitor Bpv(Hopic) enhances C2C12 myoblast migration in vitro. Requirement of PI3K/AKT and MAPK/ERK pathways. J Muscle Res Cell Motil. 2013 May; 34(2): 125-36. [5]. Raffel N, et, al. The effect of bpV(HOpic) on in vitro activation of primordial follicles in cultured swine ovarian cortical strips. Reprod Domest Anim. 2019 Aug; 54(8): 1057-1063. [6]. Ponte CD, et, al. Pharmacological postconditioning protects against hepatic ischemia/reperfusion injury. Liver Transpl. 2011 Apr; 17(4): 474-82. [7]. Zhou J,et, al. Pharmacological Inhibition of PTEN Aggravates Acute Kidney Injury. Sci Rep. 2017 Aug 25; 7(1): 9503. |
分子式 |
C6H4K2NO8V
|
---|---|
分子量 |
347.24
|
CAS号 |
722494-26-0
|
SMILES |
C1C=C(O)C=[N+]2[V]34(=O)(OO3)(OO4)OC(=O)C=12.[K+].[K+]
|
溶解度 (体外) |
H2O: 50 mg/mL (143.99 mM)
DMSO: 2.89 mg/mL (8.32 mM) |
---|---|
溶解度 (体内) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80: Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 :Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 请根据您的实验动物和给药方式选择适当的溶解配方/方案: 1、请先配制澄清的储备液(如:用DMSO配置50 或 100 mg/mL母液(储备液)); 2、取适量母液,按从左到右的顺序依次添加助溶剂,澄清后再加入下一助溶剂。以 下列配方为例说明 (注意此配方只用于说明,并不一定代表此产品 的实际溶解配方): 10% DMSO → 40% PEG300 → 5% Tween-80 → 45% ddH2O (或 saline); 假设最终工作液的体积为 1 mL, 浓度为5 mg/mL: 取 100 μL 50 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中,混合均匀/澄清;向上述体系中加入50 μL Tween-80,混合均匀/澄清;然后继续加入450 μL ddH2O (或 saline)定容至 1 mL; 3、溶剂前显示的百分比是指该溶剂在最终溶液/工作液中的体积所占比例; 4、 如产品在配制过程中出现沉淀/析出,可通过加热(≤50℃)或超声的方式助溶; 5、为保证最佳实验结果,工作液请现配现用! 6、如不确定怎么将母液配置成体内动物实验的工作液,请查看说明书或联系我们; 7、 以上所有助溶剂都可在 Invivochem.cn网站购买。 |
制备储备液 | 1 mg | 5 mg | 10 mg | |
1 mM | 2.8799 mL | 14.3993 mL | 28.7985 mL | |
5 mM | 0.5760 mL | 2.8799 mL | 5.7597 mL | |
10 mM | 0.2880 mL | 1.4399 mL | 2.8799 mL |
1、根据实验需要选择合适的溶剂配制储备液 (母液):对于大多数产品,InvivoChem推荐用DMSO配置母液 (比如:5、10、20mM或者10、20、50 mg/mL浓度),个别水溶性高的产品可直接溶于水。产品在DMSO 、水或其他溶剂中的具体溶解度详见上”溶解度 (体外)”部分;
2、如果您找不到您想要的溶解度信息,或者很难将产品溶解在溶液中,请联系我们;
3、建议使用下列计算器进行相关计算(摩尔浓度计算器、稀释计算器、分子量计算器、重组计算器等);
4、母液配好之后,将其分装到常规用量,并储存在-20°C或-80°C,尽量减少反复冻融循环。
计算结果:
工作液浓度: mg/mL;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL)。如该浓度超过该批次药物DMSO溶解度,请首先与我们联系。
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL ddH2O,混匀澄清。
(1) 请确保溶液澄清之后,再加入下一种溶剂 (助溶剂) 。可利用涡旋、超声或水浴加热等方法助溶;
(2) 一定要按顺序加入溶剂 (助溶剂) 。